PDL BioPharma (PDLI) Cash Flow Statement

Click line-items for a historical chart and %

Net income
Amortization of convertible notes offering costs	6.07M
Amortization of non-recourse notes offering costs
Other amortization and depreciation expense
Loss on retirement or conversion of convertible notes
Stock-based compensation expense
Tax (expense) benefit from stock-based compensation arrangements
Net excess tax benefit from stock-based compensation
Deferred income taxes
Receivables from licensees	-26.04M
Prepaid and other current assets	-470K
Other assets	30K
Accounts payable
Accrued liabilities	1.58M
Accrued legal settlement
Accrued income taxes
Other long-term liabilities
Deferred revenue	9.19M
Net cash provided by operating activities	86.07M
Purchases of investments	7.99M
Maturities of investments
Purchase of intangible assets
Net cash used in investing activities	-156.85M
Repurchase of convertible notes
Repayment of non-recourse notes
Cash dividend paid	-16.43M
Net proceeds from the issuance of convertible notes
Purchase of call options
Proceeds from issue of warrants
Net excess tax benefit from stock-based compensation
Net cash used in financing activities	-41.51M
Net decrease in cash and cash equivalents	-112.29M
Cash and cash equivalents at beginning of the period	218.88M
Cash and cash equivalents at end of the period	106.59M

Entities mentioned with PDLI

View All Entities